The Two Health Care Cost Crises January 18, 2024 From Drew Altman In this column, KFF President and CEO Drew Altman explores the nation’s twin health cost crises of affordability, especially for people who are sick and need a lot of health care, and national health spending, and why the solutions often work at cross purposes.
The CBO Report That Didn’t Roar January 4, 2024 From Drew Altman In his latest column, KFF President and CEO Drew Altman discusses a recent Congressional Budget Office (CBO) estimate that the Centers for Medicare and Medicaid Innovation (CMMI)’s payment and delivery demonstrations have cost Medicare money, and what it means for the future of value-based payment.
The U.S. Government and Global Health Security July 25, 2023 Issue Brief This brief examines the U.S. government’s efforts in global health security—that is, activities to help countries prepare for and develop capacities to address epidemic and pandemic diseases. It provides history and background, outlines the U.S. agencies carrying out these efforts, describes funding, and highlights key policy issues going forward.
Increasingly Privatized Public Health Insurance Programs in the US March 30, 2023 Perspective In this JAMA Forum column, KFF’s Larry Levitt examines the growing role of private insurance companies in public programs, including Medicare Advantage and Medicaid managed care, and the tradeoffs that result.
FAQs on Health Spending, the Federal Budget, and Budget Enforcement Tools March 20, 2023 Issue Brief As some policymakers in Washington are pushing to reduce the federal deficit and debt, this brief provides a concise explanation of federal spending for domestic and global health programs and services, which could be part of any conversation about curbing federal spending. These FAQs answer basic questions about health spending and the federal budget and budget enforcement tools, including the debt limit and sequestration.
How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization? March 10, 2023 Issue Brief This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.
As Debate Heats Up in Washington Over Possible Entitlement Cuts, A New KFF Analysis Details the 30% of Federal Spending That Goes to Health Care Programs March 1, 2023 News Release As some policymakers in Washington are pushing to reduce the federal deficit and debt, a new KFF resource provides a concise explanation of federal spending for domestic and global health programs and services, which could be part of any conversation about curbing federal spending. Federal spending on health programs and…
What to Know about Medicare Spending and Financing January 19, 2023 Issue Brief This brief provides an overview of Medicare spending and financing, based on the most recent historical and projected data from the Medicare Trustees and the Congressional Budget Office (CBO). The brief highlights trends in Medicare spending and key drivers of spending growth, including higher enrollment, growth in health care costs, and increases in payments to Medicare Advantage plans.
The U.S. Government and Global Polio Efforts October 3, 2022 Fact Sheet This fact sheet provides a snapshot of global polio eradication efforts and examines the U.S. government’s role in addressing polio worldwide.
U.S. Global Funding for COVID-19 by Country and Region: An Analysis of USAID Data June 29, 2022 Issue Brief As Congress again considers increased assistance for the global response to COVID-19, we look at how current U.S. global COVID-19 emergency funding is being channeled, particularly to countries and regions.